WHEN TO START? CROI 2015: Focus on ART
|
|
- Agnes Lambert
- 6 years ago
- Views:
Transcription
1 CROI 215: Focus on ART FORMATTED: Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical College New York, New York Slide 3 of 38 Learning Objectives After attending this presentation, participants will be able to: Learn about the latest findings from CROI regarding treatment. Learn about the latest findings from CROI regarding prevention. WHEN TO START? Slide 5 of 38 Washington, DC: May 13, 215 1
2 WHEN TO START? TEMPRANO: Design Slide 6 of 38 2X2 factorial design in Cote D Ivoire Eligible patients: HIV+, CD4 <8, not eligible for ART by WHO GL (N=276) Randomization: Start ART according to WHO GL Start ART according to WHO GL + INH X 6 months Start ART immediately Start ART immediately + INH X 6 months Primary ART was TDF/FTC/EFV (LPV/r or 3 NRTIs in certain cases) Primary endpoint = death, AIDS, serious bacterial infx, non-aids cancer Danel CROI 215 #115LB WHEN TO START? TEMPRANO: Results Baseline: 78% women, average age 35 yo, average CD4 465 (41% CD4 >5); 35% +Quantiferon; 9% on T/S Results: Primary endpoint (average f/u 3 months) 2.6% LTFU 24 clinical events ART: WHO (11.4%) vs. immediate (6.6%) 44% (P=.3) For subgroup with CD4 >5 WHO (1%) vs. immediate (6%) INH: yes (7%) vs. no (11%) 39% (P=.6) Sensitivity analyses (M=F, adjusted CD4, as treated) similar Slide 7 of 38 Danel CROI 215 #115LB Slide 8 of 38 WHAT TO START? Washington, DC: May 13, 215 2
3 Study Schema A5257: Phase III, prospective, multi-center, randomized, open-label trial (N=189) ART-naïve, HIV+ subjects 18 yr, VL 1 c/ml McComsey CROI 215 #14 Abstract WEAB16LB Randomized 1:1:1 to three NNRTI-sparing ARV regimens Stratified by screening HIV-1 RNA level ( or <1, copies/ml), Framingham 1-year CHD risk score (<6% vs 6% risk), and A526s participation A526s Substudy (N=328) No known CVD, diabetes mellitus, or use of lipid-lowering medications Participants followed for 96 weeks after enrollment of last subject FTC/TDF + ATV/r (N=19) A526s FTC/TDF + RAL (N=16) At baseline and week 96 DXA scan (limb fat, trunk fat and lean mass) CT abdomen (visceral and subcutaneous abdominal fat) At baseline Leptin, adiponectin, IL-6, hs-crp, D-dimer, scd14, scd163 FTC/TDF + DRV/r (N=113) Slide 9 of 38 Fat Changes: Peripheral and Central Slide 1 of 38 RAL 2% RAL 25% DRV/r 14% ATV/r 23% ATV/r 11% DRV/r 2% RAL 29% RAL 33% DRV/r 21% ATV/r 31% ATV/r 16% DRV/r 29% McComsey CROI 215 #14 Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD (N=16733 with 31 MI) Adjusted hazard ratios of MI among persons with recent ABC use (vs. no recent ABC use): Unadjusted risk: 1.88 (95% CI: 1.35, 2.6) Adjusted D:A:D model Model adjusted for cardiac risk factors Rx-naïve starting ABC Adjusted Hazard Ratio Palella CROI 215 #749 Slide 11 of 38 Washington, DC: May 13, 215 3
4 Abacavir Use and Risk for Myocardial Infarction in the NA-ACCORD Adjusted hazard ratios of select established CVD risk factors that remained significantly associated with MI in the Restricted study population Full study population Recent ABC use Age <4 (vs. 5 59) years Age 4-49 (vs. 5 59) years Age 6 (vs. 5 59) years Hypertension Diabetes egfr 3-59 (vs. 6) ml/min/1.73m 2 egfr <3 (vs. 6) ml/min/1.73m 2 High ( 24 vs. <24 mg/dl) total cholesterol High ( 3 vs. <3 mg/dl) triglycerides Statin use Slide 12 of Adusted hazard ratio for MI Palella CROI 215 #749 Slide 13 of 38 WHEN TO CHANGE & WHAT TO CHANGE TO Abstract 69, Vavro CL Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks: VIKING 3 and 4 Rx-experienced patients (including integrase inhibitors) Baseline IN Resistance and Response at Day 8 (DTG monotherapy) Slide 14 of 38 Vavro CLet al, Abstract 69, CROI Seattle 215 Washington, DC: May 13, 215 4
5 Integrase Resistance Correlates of Response to Dolutegravir (DTG) Through 48 Weeks (VIKING 3 and 4) Study Population: VL >5K; virologic failure on RAL or EVG; optimized background at 7 days DTG 5 mg BID (ITT-E, Snapshot Algorithm) Baseline IN Mutation Group Week 24 <5 c/ml Week 48 <5 c/ml N N (%) N (%) All (66%) 128 (6%) No Q (78%) 98 (7%) Q * (52%) 23 (48%) Q * 25 6 (24%) 7 (28%) *L74I, E138A/K/T, G14A/C/S Slide 15 of 38 Vavro CROI 215 Abstract #69 Phase 3 Phase 2 Phase 1/2 TAF Newer ART Agents (partial list) NRTI NNRTI PI Entry Inh apricitabine BILR 355 dexelvucitabine doravirine festinavir (MK-1439) elvucitabine TMC Phase 1 CMX157 RDEA 86 CTP-298 CTP-518 PPL-1 SPI-256 cenicriviroc BMS ibalizumab PF HGS4 SCH53276 VIR-576 II cabotegravir (GSK 744) BI INH-11 MI BMS GSK Slide 16 of 38 Drug Delivery: TDF vs. Tenofovir Alafenamide Fumarate (TAF) Slide 17 of 38 Washington, DC: May 13, 215 5
6 Mean (SD) Change from Baseline egfr* HIV-1 RNA <5 c/ml, % TAF: Phase 3 Study Design: Studies 14 and 111 Tx-Naïve Adults (N=1733) HIV-1 RNA 1 c/ml egfr 5 ml/min 1:1 n=866 n=867 E/C/F/TAF QD E/C/F/TDF QD Two Phase 3 randomized, double-blind, double-dummy, active-controlled studies Study 14 (North America, EU, Asia), Study 111 (North America, EU, Latin America) Primary endpoint: proportion of patients with HIV-1 RNA <5 copies/ml Non-inferiority (12% margin) based on Week 48 FDA snapshot analysis Combined efficacy analysis pre-specified Week Primary Endpoint Slide 18 of 38 Wohl CROI 215 #113LB TAF Phase 3: VL <5 copies/ml at Week 48 Studies 14 and 111: Week 48 Combined Analysis Virologic Outcome E/C/F/TAF (n=866) E/C/F/TDF (n=867) Success Failure No Data Treatment Difference (95% CI) Favors E/C/F/TDF.7% E/C/F/TAF non-inferior to E/C/F/TDF at Week 48 Comparable responses by baseline VL and CD4 Favors E/C/F/TAF 2.% 4.7% 12% +12% Wohl CROI 215 #113LB Slide 19 of 38 *Cockroft-Gault (ml/min). TAF: Phase 3 Change in egfr (Cockcroft-Gault) Studies 14 and 111: Week 48 Combined Analysis Mean (SD) change from baseline egfr Cockroft-Gault (ml/min) Time (Weeks) Time (Weeks) No cases of proximal renal tubular dysfunction (Fanconi s syndrome) E/C/F/TAF E/C/F/TDF p <.1 Slide 2 of 38 Sax CROI 215 #143LB Washington, DC: May 13, 215 6
7 Mean (SD) % Change from Baseline Slide 21 of 38 Changes in Spine and Hip BMD Through Week 48 Studies 14 and 111: Week 48 Combined Analysis Spine Hip p < p < Week Week E/C/F/TAF, n E/C/F/TDF, n Sax CROI 215 #143LB Cabotegravir (CAB, GSK ) Integrase inhibitor similar to DTG; similar resistance Potent in HIV+ individuals (5, 1, 3, 6 mg oral) Margolis EACS 213; Spreen HIV Clin Trials 213;14:192 Nanotechnology formulation; SC + IM injections T ½ 21-5 days! Supports monthly or quarterly dosing Safety: ISR (all mild) and nodules with SC dosing Spreen JAIDS 214;67:481 Slide 22 of 38 LATTE 1: CAB and RPV as 2-Drug Oral Maintenance Therapy Study Design Slide 23 of 38 HIV ART-naïve HIV-1 RNA 1 c/ml CD4 2 cells/mm 3 1:1:1:1 Randomization Stratified by VL and NRTI Blinded to CAB dose N=243 Oral Induction Phase Oral Maintenance Phase CAB 1 mg + 2 NRTIs* CAB 1 mg + RPV 25 mg CAB 3 mg + 2 NRTIs CAB 3 mg + RPV 25 mg CAB 6 mg + 2 NRTIs CAB 6 mg + RPV 25 mg EFV 6 mg + 2 NRTIs *ABC/3TC or TDF/FTC D Margolis CROI 215, #554LB Washington, DC: May 13, 215 7
8 LATTE 1: Week 96 results CAB and RPV Oral Maintenance Therapy Virologic Success: HIV-1 RNA <5 c/ml by FDA Snapshot (ITT-E) Proportion, % (95% CI) 1 BL Median CD4+ cell count (IQR) CAB total n=16 EFV 6 mg n=47* Baseline 412. (333., 548.) (34., 651.) Change from Baseline at W96 CAB 1 mg (n=6) (137., 355.) (158., 415.) CAB 6 mg (n=61) CAB 3 mg (n=6) EFV 6 mg (n=62) Slide 24 of 38 Margolis CROI 215, #554LB BMS-66368: Oral HIV Attachment Inhibitor Prodrug of BMS Inhibits CD4 binding by binding to gp12 PK suggest QD or BID dosing without boosting baseline susceptibility in some pts due to envelope polymorphisms; screened by baseline IC 5 Slide 25 of 38 Study pop: CD4 >2, VL >5 off ART X >8 wks or ART-naive (N=5) Nettles JID 212;26:12 BMS-66368: Phase 2b Randomized, partially blinded (to 68 dose) Rx-experienced pts (>1 wk on >1 ART) with IC5<1nM for 529 (N=251) Randomized to TDF + RAL + 68 [4 or 8 bid; 6 or 12 qd] or ATV/r Results: 8d monotherapy: up to 1.5 log with 12 mg qd Wk 48 VL < % vs. ATV/r 71%; no difference by BL VL or CD4 68: no SAE or rx d/c 6 mg bid selected for phase 3 Thompson CROI 215 #545 Landry CROI 215 #59 Slide 26 of 38 Washington, DC: May 13, 215 8
9 Maturation Inhibitors Slide 27 of 38 Lataillade CROI 215, #114LB Study population: HIV+, VL >5K, CD4 >2, PI and MI naive No serious adverse events, grade 3/4 events, no d/c due to adverse events Plans for phase 2b Slide 28 of 38 Lataillade CROI 215, #114LB PREVENTION Slide 29 of 38 Washington, DC: May 13, 215 9
10 PROUD Pilot GMSM reporting UAI last/next 9days; 18+; and willing to take a pill every day Randomize HIV negative MSM (N=545) (exclude if treatment for HBV/TDF + FTC contra-indicated) Risk reduction includes TDF + FTC NOW Risk reduction includes TDF + FTC AFTER 12M Follow 3 monthly for up to 24 months Main endpoints in Pilot: recruitment and retention From April 214: HIV infection in first 12 months McCormack CROI 215 #22LB Slide 3 of 38 HIV Incidence Group No. of Followup (PY) (per 1 Incidence infections PY) 9% CI Overall Immediate Deferred Efficacy =86% (9% CI: 58 96%) P value =.2 Rate Difference =7.6 (9% CI: ) Number Needed to Treat =13 (9% CI: 9 25) McCormack CROI 215 #22LB Slide 31 of 38 N=414 n=26 n=28 Molina CROI 215 #23LB Slide 32 of 38 Washington, DC: May 13, 215 1
11 Molina CROI 215 #23LB Slide 33 of 38 Slide 34 of new infections 2 new infections Molina CROI 215 #23LB FACTS 1 Phase III RCT 18-3 years, HIV negative, sexually active women Not pregnant, Willing to use effective contraception and condoms No renal, hepatic, pelvic or bone disease Enrolled irrespective of HSV-2, Hepatitis B or breastfeeding status Randomised to pericoital use (BAT 24) (N=259) Vaginal TFV 1% gel Monthly visits 1-27 months HIV testing, safety assessment, product resupply and quarterly CVL Placebo gel Comprehensive HIV prevention counselling, provision of condoms and contraception, treatment for symptomatic STIs Primary endpoint = HIV infection Rees CROI 215 #26LB Slide 35 of 38 Washington, DC: May 13,
12 Cumulative proportion of HIV endpoints Primary outcome: cumulative HIV incidence by trial arm (mitt) Time from randomisation (months) Placebo TFV gel TFV gel: 61 Log-rank test stratified by site, p=.95 placebo: 62 HIV incidence 4%/year overall No difference in HIV incidence between TFV gel vs placebo Rees CROI 215 #26LB Slide 36 of 38 Acknowledgments Cornell HIV Clinical Trials Unit (CCTU) Division of Infectious Diseases Weill Cornell Medical College AIDS Clinical Trials Group (ACTG) HIV Prevention Trials Network (HPTN) Division of AIDS, NIAID, NIH Multiple colleagues for slides The patient volunteers! Slide 38 of 38 Washington, DC: May 13,
Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York
Antiretroviral Therapy: Investigational New Drugs and New Strategies Roy M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Weill Cornell Medicine New York, New York FORMATTED: MM/DD/YY Antiretroviral
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationLong-Acting Antiretrovirals for HIV
Long-Acting Antiretrovirals for HIV R.M. Gulick, MD, MPH Rochelle Belfer Professor in Medicine Chief, Division of Infectious Diseases Weill Cornell Medicine New York City Disclosures None Single Tablet
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationCROI 2013: New Drugs for Treatment and PrEP
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2013: New Drugs for Treatment and PrEP Brian R. Wood, MD Medical Director, NW AETC Project ECHO Assistant Professor of Medicine, University of Washington
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationCabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016
Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team RPV CAB CAB RPV 1 June 2016 Cabotegravir Long-Acting Nanosuspension CAB is an investigational
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationAntiretroviral Treatment: What's in the Pipeline
Antiretroviral Treatment: What's in the Pipeline Joseph P. McGowan, MD, FACP, FIDSA Professor of Medicine Hofstra North Shore-LIJ School of Medicine October 14, 2015 Which describes best how HIV Maturation
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationDidactic Series. CROI Update - II. Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15
Didactic Series CROI Update - II Christian B. Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic 5/28/15 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More information11/7/2016. Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama
HIV Preexposure Prophylaxis: Pills, Rings, Injectables, and Gels Oh My! Jeanne M. Marrazzo, MD, MPH Professor of Medicine University of Alabama at Birmingham Birmingham, Alabama FORMATTED: 10/17/16 Financial
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationTenofovir Alafenamide (TAF)
Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016
More informationTerapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R
Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,
More information4/14/2016. Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections
Breaking News From the 2016 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University School of Medicine
More informationHIV Treatment Update 8/3/2015. When to Start. Disclosures
8/3/215 HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationIAS 2015: Return to Vancouver
IAS 2015: Return to Vancouver Paul E. Sax, M.D. Clinical Director, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School NEAETC Memories from 1996 First
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationART Treatment. ART Treatment
Naïve Experienced Strategies ARV in pregnancy ART Treatment Naïve studies: ART Treatment Abstract 37 Atazanavir/r vs Lopinavir/r: Castle study Abstract 774 Kivexa vs Truvada: HEAT study Abstract 775 Lopinavir/r
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationFuture Perspectives for Delivery of Antiretroviral Drugs
Future Perspectives for Delivery of Antiretroviral Drugs David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationClinical Pharmacology Related Considerations.
Clinical Pharmacology Related Considerations. David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS,
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationDidactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16
Didactic Series Bone Health in the context of HIV Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 This project is supported by the Health Resources and Services Administration
More information23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service,
23 rd CROI Report Back AETC/Community Consortium Harry W. Lampiris, MD Professor of Clinical Medicine, UCSF Chief, ID Section, Medical Service, SFVAMC March 23, 2016 Boston, MA, February 22-25, 2016 Disclosures
More informationChronic complications of HIV infection. An update Pablo Tebas, MD
Activity Code TM809 Chronic complications of HIV infection. An update 2014 Pablo Tebas, MD Learning Objectives Upon completion of this presentation, learners should be better able to: Identify and update
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationTreatment update. Bronagh McBrien June 2016
Treatment update Bronagh McBrien June 2016 Speaker Name Bronagh McBrien Statement Received educational funding and support from Gilead, Merck, Boehringer Ingelheim, Janssen-Cilag Date : 27 June 2016 BHIVA
More informationAntiretroviral Therapy Where we are and where we are going
Antiretroviral Therapy Where we are and where we are going Joe Eron, MD Professor Medicine UNC Chapel Hill February 2016 Disclosures Dr. Eron received research grants awarded to his institution from AbbVie,
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationThe impact of antiretroviral drugs on renal function
The impact of antiretroviral drugs on renal function Professor Bruce Hendry Renal Medicine King s College London King s College Hospital NHS Foundation Trust 1 DISCLOSURES: BRUCE HENDRY I have received
More informationFat redistribution on ARVs: dogma versus data
Fat redistribution on ARVs: dogma versus data Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Half of what we are going to teach
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationUnderstanding the unmet medical needs with current ART
Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO, Trip Gullik Industry: Gilead, Janssen,
More informationAntiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies. Joel Gallant, MD, MPH Johns Hopkins University School of Medicine
Antiretroviral Therapy: Current Recommendations, New Drugs, and Novel Strategies Joel Gallant, MD, MPH Johns Hopkins University School of Medicine Initial Regimen: DHHS Guidelines 3/27/2012 Preferred Regimens
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationCROI 2015: Treatment and Cure Highlights
NORTHWEST AIDS EDUCATION AND TRAINING CENTER CROI 2015: Treatment and Cure Highlights Shireesha Dhanireddy Robert Harrington March 17, 2014 No financial conflicts of interest Outline Treatment Studies
More informationOral Versus Injectable Delivery, Impact on Adherence/Tolerability
Oral Versus Injectable Delivery, Impact on Adherence/Tolerability 2 nd European HIV Forum Ian McGowan MD DPhil FRCP University of Pittsburgh, PA, USA Glasgow, 22 nd October, 2016 Overview Why do we need
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 COMPLICATIONS OF HIV DISEASE AND TREATMENT Overview Cardiovascular
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationBHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh
BHIVA Best of CROI Feedback Meetings London Birmingham North West England Cardiff Gateshead Edinburgh BHIVA Best of CROI Feedback Meetings 2010 ANTIRETROVIRAL TREATMENT STRATEGIES AND NEW DRUGS A5202:
More informationBHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes
BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what
More information2017 NSTC Annual Meeting Eric Daar April 18, 2017
Antiretroviral Therapy Update for TB Clinicians Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grants Consultant
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationProfessor Jeffery Lennox
BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Professor Jeffery Lennox Emory University School of Medicine Atlanta, Georgia, USA 9-10 October 2014, Queen Elizabeth II Conference Centre,
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationIntegrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University
Integrase Inhibitors in the Treatment HIV-Infection Andrew Zolopa, MD Stanford University 1 IAS-USA 212 Guidelines Updated Recommendations When to start ART is now recommended for all patients, regardless
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationL infettivologia del 3 millennio: AIDS ed altro
L infettivologia del 3 millennio: AIDS ed altro VI Convegno Nazionale 15-16 -17 maggio 2014 Centro Congressi Hotel Ariston Paestum (SA) Nuove molecole ad azione anti-hiv Annalisa Saracino Clinica Malattie
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationLong Acting ART for Treatment and PrEP
Long Acting ART for Treatment and PrEP Anton Pozniak MD FRCP Consultant Physician Disclosures I have received honoraria, travel sponsorship and research grants from: Gilead Sciences Janssen MSD ViiV Healthcare
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More information